Podcasts about reachmd

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personalized, tumor-informed ctDNA assay; those testing positive for ctDNA were randomized to receive atezolizumab or placebo, while ctDNA-negative patients continued surveillance without treatment. The trial demonstrated significant improvements in both disease-free and overall survival in the atezolizumab group along with favorable outcomes among ctDNA-negative patients, suggesting many may safely avoid overtreatment. Joining Dr. Charles Turck to unpack the study results and how they highlight ctDNA's role in guiding personalized therapy is Dr. Andrea Necchi. Not only is he an investigator on this research, but he's also an Associate Professor of Oncology at Vita-Salute San Raffaele University and the Director of Genitourinary Medical Oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan, Italy.

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.

Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest translational insights into resistance mechanisms, including genomic alterations affecting cell cycle and signal transduction pathways, and discusses evolving therapeutic strategies. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School and the Director of Precision Medicine at the Termeer Center for Targeted Therapies at Mass General Brigham Cancer Institute. He also spoke about this topic at the 2025 San Antonio Breast Cancer Symposium.

Guest: Gerard A. Silvestri MD, MS, Master FCCP Guest: Adam H. Fox, MD, MSc Guest: Anurag Singh, MD, PhD From updated surveillance strategies to evolving biopsy techniques and treatment advances, recent findings presented at 2025 conferences are reshaping non-small cell lung cancer management. Dr. Gerard Silvestri speaks with Drs. Adam Fox and Anurag Singh to explore key data influencing diagnostic decisions, patient-centered care, and multidisciplinary treatment planning across stages. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Guest: Gerard A. Silvestri MD, MS, Master FCCP Guest: Mariam Alexander, MD, PhD Guest: Jessica S. Donington, MD, MSCR The 2025 European Society for Medical Oncology Congress and World Conference on Lung Cancer revealed significant updates in non-small cell lung cancer care. Learn more as Drs. Gerard Silvestri, Mariam Alexander, and Jessica Donington review new data on EGFR- and ROS1-targeted therapies, perioperative immunotherapy, and multidisciplinary strategies to expand resectability in stage III non-small cell lung cancer. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Alexander is an Assistant Professor of Medical Oncology at the Medical University of South Carolina. Dr. Donington is a Professor in Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.

Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest translational insights into resistance mechanisms, including genomic alterations affecting cell cycle and signal transduction pathways, and discusses evolving therapeutic strategies. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School and the Director of Precision Medicine at the Termeer Center for Targeted Therapies at Mass General Brigham Cancer Institute. He also spoke about this topic at the 2025 San Antonio Breast Cancer Symposium.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Cogle, PharmD, BCNSP, FASPEN Evolving evidence supports the shift from single-source to multi-source intravenous lipid emulsions in parenteral nutrition. These newer formulations may offer improved metabolic, inflammatory, and hepatic outcomes, particularly for vulnerable patient populations. Joining Dr. Charles Turck to discuss the clinical rationale and operational considerations for these formulations is Dr. Sarah Cogle, who's a Clinical Pharmacist Specialist at Vanderbilt University Medical Center in Nashville, Tennessee.

Host: Ryan Quigley Guest: Kathrin M. Bernt, MD Guest: Rushabh Mehta, BS Guest: Fatemeh Alikarami New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their findings could impact minimal residual disease detection, therapy resistance, and future risk stratification strategies. Dr. Bernt is a pediatric oncologist and an Associate Professor of Pediatrics at the Children's Hospital of Philadelphia. Dr. Alikarami is a Research Associate Scientist at the Children's Hospital of Philadelphia. Mr. Mehta is a PhD candidate in cell and molecular biology at the University of Pennsylvania.

Host: Brian P. McDonough, MD, FAAFP Guest: Matthew Galsky, MD Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial's long-term data, which show sustained disease-free survival and highlight ctDNA's potential as a marker for residual disease. These findings reinforce nivolumab's role in the evolving standard of care and may support more personalized post-surgical strategies. Dr. Galsky is a Professor of Medicine and the Director of Genitourinary Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York.

Host: Ryan Quigley Guest: Kathrin M. Bernt, MD Guest: Rushabh Mehta, BS Guest: Fatemeh Alikarami New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their findings could impact minimal residual disease detection, therapy resistance, and future risk stratification strategies. Dr. Bernt is a pediatric oncologist and an Associate Professor of Pediatrics at the Children's Hospital of Philadelphia. Dr. Alikarami is a Research Associate Scientist at the Children's Hospital of Philadelphia. Mr. Mehta is a PhD candidate in cell and molecular biology at the University of Pennsylvania.

Host: Jennifer Caudle, DO Guest: Wendy Wright, DNP, FNP-BC, ANP-BC Randomized controlled trials have shown data supporting the safety and efficacy of cell-based influenza vaccines in adults and children.1-4 However, effectiveness studies have historically relied on outcomes based on clinical diagnosis of influenza-like illness rather than test-confirmed influenza.5 Test-confirmed influenza outcomes provide a more specific evaluation of influenza vaccine effectiveness and can help reveal the clinical differences between cell-based versus egg-based vaccines.6 A retrospective test-negative real-world study including more than 106,000 patients compared the cell-based vaccine with egg-based vaccines.7 Dr. Jennifer Caudle sits down with Dr. Wendy Wright to review the key findings from this analysis and their implications. Dr. Wright is a board-certified adult and family nurse practitioner based out of Amherst, New Hampshire as well as the owner of Wright and Associates Family Healthcare. References: FLUCELVAX. Package insert. Seqirus Inc. Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother. 2016;12(9):2278–88. doi:10.1080/21645515.2016.1182270. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51(9):997–1004. doi:10.1086/656578. Diez-Domingo J, de Martino M, Lopez …

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. Dr. Brian Slomovitz discusses how lifestyle interventions and emerging therapies may reduce cancer recurrence. He's the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victoria Coleman-Cowger as she highlights recommendations for supporting emotional wellbeing during and after gene therapy and explains the importance of recognizing both the psychological and social impacts of curative treatment. Dr. Coleman-Cowger is a licensed clinical psychologist and the Associate Vice President of Neurology and Cell and Gene Therapy at Emmes, a full-service clinical research foundation.

Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer's diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer's disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference.

Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victoria Coleman-Cowger as she highlights recommendations for supporting emotional wellbeing during and after gene therapy and explains the importance of recognizing both the psychological and social impacts of curative treatment. Dr. Coleman-Cowger is a licensed clinical psychologist and the Associate Vice President of Neurology and Cell and Gene Therapy at Emmes, a full-service clinical research foundation.

Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer's diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer's disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference.

Host: Ryan Quigley Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.

Host: Ryan Quigley How are patients with breast cancer brain metastases faring in the modern treatment era? In this AudioAbstract, Ryan Quigley shares findings from a 25-year review of 507 patients at UCSF, providing new insights into how survival outcomes have shifted across subtypes and which treatments are driving real-world progress. This research was also presented at the 2025 San Antonio Breast Cancer Symposium.

Host: Ryan Quigley Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.

Host: Ryan Quigley How are patients with breast cancer brain metastases faring in the modern treatment era? In this AudioAbstract, Ryan Quigley shares findings from a 25-year review of 507 patients at UCSF, providing new insights into how survival outcomes have shifted across subtypes and which treatments are driving real-world progress. This research was also presented at the 2025 San Antonio Breast Cancer Symposium.

Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.

Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.

A look at the intersection of Artificial Intelligence and Healthcare. The Convergence can be found on ReachMD.comDr Brian McDonough is the host of this impactful series

CME credits: 0.25 Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of plaque psoriasis. Investigation into novel oral small-molecule therapies is ongoing, such as next-generation TYK2 inhibitors and the first-in-class investigational targeted oral peptide icotrokinra, which selectively targets IL-23 receptor signaling. These therapies have demonstrated dramatically improved clinical responses versus comparators and may significantly impact the current treatment paradigm for plaque psoriasis. =

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Blood-based colorectal cancer screening is entering a new era with FDA-approved and emerging tests like Shield and Simple Screen. Alongside updated stool-based options such as Cologuard Plus and CRC-PREVENT, clinicians now have a broader landscape of noninvasive tools to consider and discuss with their patients. Joining Dr. Peter Buch to talk about current recommendations and potential future directions for colorectal cancer screening is Dr. Aasma Shaukat. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor of Population Health at NYU Grossman School of Medicine, as well as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health. She's also a co-author of a recent review on blood tests for colorectal cancer.

Guest: Brian Gill, M.D. Brian Gill, M.D., a neurosurgeon at NewYork-Presbyterian and Columbia, talks about a new clinical trial evaluating a device that can temporarily open the blood-brain barrier (BBB) to more effectively treat glioblastoma. Dr. Gill explains how this new sonication device uses focused ultrasound to temporarily disrupt the BBB in order to administer chemotherapy directly into the tumor bed. The trial is building on promising results from phase 1 and phase 2 trials, which demonstrated safety, efficacy, and the potential to enhance quality of life for patients with recurrent glioblastoma. © 2025 NewYork-Presbyterian

Host: Brian P. McDonough, MD, FAAFP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP With the potential to reduce infection risk, improve operational efficiency, and enhance safety through standardization, multi-chamber bags are increasingly being used as an alternative to traditional compounded parenteral nutrition. To explore this approach and how it can be implemented in hospital and home care settings, Dr. Brian McDonough speaks with Dr. George Phillip Ayers. He's an Associate Clinical Professor at the University of Mississippi School of Pharmacy as well as the Chief of Clinical Pharmacy Services in the Department of Pharmacy at the Mississippi Baptist Medical Center in Jackson.

Host: Jennifer Caudle, DO Guest: Samuel Klempner, MD Guest: Nataliya Uboha, MD, PhD Testing for biomarkers like PD-L1, HER2, claudin 18.2, and FGFR2b is reshaping our approach to first-line therapy in advanced gastric and gastroesophageal junction cancers. Alongside biomarker profiling, we must also weigh practical considerations around efficacy, toxicity, and patient-specific factors when selecting treatment. Joining Dr. Jennifer Caudle to explore how we can optimize our first-line treatment selection are Drs. Samuel Klempner and Dr. Nataliya Uboha. Dr. Klempner is an Associate Professor of Medicine at Harvard Medical School, and Dr. Uboha is an Associate Professor in the Division of Hematology and Oncology in the Department of Medicine at the University of Wisconsin.

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia. =

CME credits: 0.25 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-based-approach-optimizing-cardio-kidney-metabolic-outcomes-in-individuals-with-t2d-ckd/29906/ This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence from the CONFIDENCE and other trials, the discussion highlights the benefits and safety of early combination therapy with finerenone and SGLT2i, and GLP-1 receptor agonists. Practical strategies are shared to support primary care teams in integrating these therapies and reducing long-term cardio-kidney-metabolic risk. =

CME credits: 0.25 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/ Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.=

CME credits: 0.50 Valid until: 29-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/ This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making. =

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Adams, MD Hemochromatosis, a genetic condition that causes the body to absorb too much iron from food, often goes unrecognized despite its prevalance. With unique diagnostic and management challenges, it's crucial to understand how it presents, which testing strategies are most effective, and what treatment options are available. Tune in to hear Dr. Peter Buch and Dr. Paul Adams, Professor in the Division of Gastroenterology at the Western University in London, Canada, discuss the latest on hemochromatosis.

Guest: Joel Gabre, M.D, MPH On this episode of Advances in Care, host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon. In addition, Dr. Gabre shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and how clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team's recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers. Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first-hand the rise in colon cancer rates among his younger patients. He shares a story of what …

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That's why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39278/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39666/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-unmet-therapeutic-needs/39665/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/treatment-of-overt-hepatic-encephalopathy/39664/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-whats-sarcopenia-got-to-do-with-it/39663/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/diagnosing-minimal-hepatic-encephalopathy-theres-an-app-for-that/39662/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-tipping-the-balance/39660/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/the-clinical-spectrum-of-hepatic-encephalopathy/39304/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical and psychosocial outcomes, examine tools to advance equity and shared decision-making, and evaluate the latest evidence for GnRH antagonists as a nonsurgical treatment strategy. The session concludes with a patient perspective that illustrates how lived experience can inform more patient-centered, multidisciplinary care that incorporates medical treatment and shared decision-making. =

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/ This WHAV 2025 session examines primary biliary cholangitis (PBC), a chronic autoimmune liver disease that predominantly affects women and often goes unrecognized. Tailored for clinicians who play a key role in identifying symptoms and initiating referrals, the session outlines diagnostic criteria—including AMA positivity and elevated ALP—and clarifies when specialist evaluation is warranted. Treatment strategies cover UDCA and newer agents like elafibranor and seladelpar for nonresponders. The discussion also addresses symptom burden, extrahepatic manifestations, and reproductive-stage considerations, including pregnancy. =

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Charles Kahi, MD Computer-aided detection systems (CADe) are transforming adenoma detection and enhancing colonoscopy quality. Dr. Peter Buch sits down with Dr. Charles Kahi to unpack the latest American Gastroenterological Association (AGA) guideline, evidence from randomized controlled trials, and the practical implications of integrating AI tools into clinical practice. Dr. Kahi is a Professor of Medicine at Indiana University School of Medicine, and he helped develop the AGA Living Clinical Practice Guideline on Computer-Aided Detection-Assisted Colonoscopy, which was published in Gastroenterology in 2025.